prikaz prve stranice dokumenta Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
  Preuzmi
PDF 299.68 KB
Znanstveni rad - Izvorni znanstveni rad
Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
International Journal of Molecular Sciences, 24 (2023), 16; 12840. https://doi.org/10.3390/ijms241612840
Janzic, Urska; Shalata, Walid; Szymczak, Katarzyna; Dziadziuszko, Rafał; Jakopović, Marko; Mountzios, Giannis; Płużański, Adam; Araujo, Antonio; Charpidou, Andriani; Agbarya, Abed

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Janzic, U., Shalata, W., Szymczak, K., Dziadziuszko, R., Jakopović, M., Mountzios, G. ... Agbarya, A. (2023). Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations. International Journal of Molecular Sciences, 24. (16). doi: 10.3390/ijms241612840

Janzic, Urska, et al. "Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations." International Journal of Molecular Sciences, vol. 24, br. 16, 2023. https://doi.org/10.3390/ijms241612840

Janzic, Urska, Walid Shalata, Katarzyna Szymczak, Rafał Dziadziuszko, Marko Jakopović, Giannis Mountzios, Adam Płużański, Antonio Araujo, Andriani Charpidou i Abed Agbarya. "Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations." International Journal of Molecular Sciences 24, br. 16 (2023). https://doi.org/10.3390/ijms241612840

Janzic, U., et al. (2023) 'Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations', International Journal of Molecular Sciences, 24(16). doi: 10.3390/ijms241612840

Janzic U, Shalata W, Szymczak K, Dziadziuszko R, Jakopović M, Mountzios G, i sur.. Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations. International Journal of Molecular Sciences [Internet]. 16.08.2023. [pristupljeno 22.11.2024.];24(16). doi: 10.3390/ijms241612840

U. Janzic, et al., "Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations", International Journal of Molecular Sciences, vol. 24, br. 16, Kolovoz 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:099032. [Citirano: 22.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:099032
Podaci o radu
Naslov (engleski)Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
AutorUrska Janzic
AutorWalid Shalata
AutorKatarzyna Szymczak
AutorRafał Dziadziuszko
AutorMarko Jakopović
AutorGiannis Mountzios
AutorAdam Płużański
AutorAntonio Araujo
AutorAndriani Charpidou
AutorAbed Agbarya
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs. 39.1% (p = 0.04), respectively. The type of treatment in first-line TT vs. other affected time to treatment discontinuation (TTD) was 11.6 m vs. 4.6 m (p= 0.006). The overall survival for the whole group was 15.4 m and was not statistically affected by the type of treatment (19.2 m vs. 13.5 m; p = 0.83).
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaInternational Journal of Molecular Sciences
Brojčani podacivol. 24, br. 16, 12840
e-ISSN1422-0067
DOIhttps://doi.org/10.3390/ijms241612840
URN:NBNurn:nbn:hr:105:099032
Datum objave publikacije2023-08-16
URL dokumentahttps://www.mdpi.com/1422-0067/24/16/12840
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-08-19 09:06:52